Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 680 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 2 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

NCT00240877
View directory record Official record
Conditions
Influenza
Interventions
AV024, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2008 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
12 Years and older
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 17, 2026, 6:37 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

NCT06838000
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Months to 17 Years
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
17
States / cities
Paramount, California • Doral, Florida • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01335347
View directory record Official record
Conditions
Avian Influenza, Bird Flu
Interventions
ND1.1, Placebo control
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

NCT02434276
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q, Fluzone Quadrivalent
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 17, 2026, 6:37 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Intradermal Influenza Vaccination

NCT06067555
View directory record Official record
Conditions
Vaccine Reaction
Interventions
MicronJet, Fluzone® Quadrivalent, Bacteriostatic Saline
Device · Biological · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 17, 2026, 6:37 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 17, 2026, 6:37 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

NCT03191383
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Newton, Kansas • Syracuse, New York • Ellensburg, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes

NCT06127251
View directory record Official record
Conditions
Obesity
Interventions
PATH Intervention, Control Group, Physical activity tracker, Dietary education
Behavioral · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
31 valent pneumococcal conjugate vaccine, PCV20, PCV21
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,049 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

NCT06615375
View directory record Official record
Conditions
Shigellosis
Interventions
Shigella4V2, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

NCT05164094
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1189, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
10 Years to 30 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
65
States / cities
Huntsville, Alabama • Anaheim, California • Colton, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

NCT03505060
View directory record Official record
Conditions
HIV Infections
Interventions
DNA CON-S env, IHV01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 17, 2026, 6:37 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
View directory record Official record
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Vaccine for Recurrent Urinary Tract Infections in Women

NCT00261248
View directory record Official record
Conditions
Recurrent Urinary Tract Infections in Women
Interventions
Immunization with inactivated bacteria
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 17, 2026, 6:37 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638
View directory record Official record
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions
INO-4800, CELLECTRA® 2000, Placebo
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults

NCT00480155
View directory record Official record
Conditions
Healthy
Interventions
Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance

NCT05764174
View directory record Official record
Conditions
Vaccination Refusal, COVID-19
Interventions
Factual messages, Narrative message, Mixed message
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

NCT04009824
View directory record Official record
Conditions
Mosquito-Borne Infectious Diseases
Interventions
AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, Alhydrogel® Adjuvant, Saline Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

NCT04626297
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
85
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 6:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness

NCT05006833
View directory record Official record
Conditions
HPV
Interventions
Brief Provider Training - Bundled Approach, Brief Provider Training - Benefits Approach, Parent Interactive Text Message - Bundled Approach, Parent Interactive Text Message - Benefits Approach
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
10 Years and older
Enrollment
8,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 17, 2026, 6:37 AM EDT